Multiple Sclerosis | Treatment Algorithms: Claims Data Analysis | US | 2024
The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; more than 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the disease, and more are in the pipeline. A variety of drug classes comprise the MS therapy market owing to the disease’s heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. However, with each new launch and growing generics competition, the market is becoming increasingly crowded; meanwhile, early intervention with high-efficacy drugs continues to gain traction in lieu of the prevailing escalation paradigm. Thus, players engaged in or entering this space must assess where their products, especially next-in-class alternatives, will fit. Our Treatment Algorithms study provides national patient-level claims data analysis that shows the treatment progression by line of therapy, persistence and compliance by brand, and the positioning of current DMTs.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MS patients?
- How have anti-CD20 monoclonal antibodies been integrated into the treatment algorithm, and what are their sources of business? What impact has the emergence of Briumvi and Kesimpta had on the prescribing of Ocrevus?
- Are generic oral therapies having a discernible impact on prescribing patterns?
- What percentage of MS patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan / Viatris, Novartis, Sanofi, Teva, TG Therapeutics
Key drugs: Aubagio / teriflunomide, Bafiertam, Briumvi, Copaxone / glatiramer acetate, Gilenya / fingolimod, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera / dimethyl fumarate, Tysabri, Vumerity, Zeposia
Key analysis provided:
- Brand / therapy usage across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
